Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MYAMBUTOL vs PASER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
Treatment of tuberculosis in combination with other antituberculosis drugs,Off-label: None
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
Terminal elimination half-life is 1.5 to 2.5 hours in patients with normal renal function. In anuria or severe renal impairment (Cr Cl <10 m L/min), half-life may extend to 8-12 hours. Clinical context: Accumulation occurs with renal failure, requiring dose adjustment.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Hepatic via N-acetyltransferase (polymorphic acetylation); major metabolite is acetyl-PAS.
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
Renal excretion accounts for approximately 80% of the administered dose, with about 60-70% as unchanged drug and 10-20% as metabolites (primarily acetylated). The remainder is excreted via feces (approximately 10-15%) and minor biliary elimination. Renal clearance is highly dependent on glomerular filtration rate.
20-30% bound to albumin.
Protein binding is approximately 10-15%, primarily to albumin. Binding is low, nonlinear, and saturable at high concentrations.
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Volume of distribution is 0.5-0.7 L/kg, indicating distribution into total body water. Clinical meaning: Moderate distribution suggests penetration into well-perfused tissues but limited CNS penetration unless inflamed.
Oral: approximately 80% absorbed.
Oral bioavailability is approximately 70-80% (range 60-90%). Food decreases the rate and extent of absorption, with AUC reduction of about 20-40%.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Contraindicated in severe renal impairment (Cr Cl <30 m L/min). For Cr Cl 30-50 m L/min: reduce dose to 4 g orally every 12 hours; monitor serum concentrations. Use with caution in moderate impairment.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
No specific dose adjustment guidelines for Child-Pugh classification. Use with caution in severe hepatic impairment due to potential hepatotoxicity; monitor liver function tests.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Not recommended for children (safety and efficacy not established).
Consider reduced initial dose based on renal function; monitor for optic neuritis.
Lower initial doses may be considered due to age-related decline in renal function. Monitor renal function and serum concentrations closely.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
None
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
May cause hypothyroidism, hepatitis, and crystalluria. Use with caution in patients with renal impairment or glucose-6-phosphate dehydrogenase deficiency.
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Hypersensitivity to para-aminosalicylic acid or any component; severe renal impairment.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
Take with food to reduce gastrointestinal irritation. Avoid high-fat meals as they may delay absorption. Avoid alcohol.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Second and third trimesters: No known major malformations; risks may include gastrointestinal intolerance in mother. Advised use only if clearly needed.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
Excreted into breast milk in small amounts. M/P ratio unknown. Considered compatible with breastfeeding by American Academy of Pediatrics; monitor infant for diarrhea or rash.
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
No dosing adjustment required for pregnancy. Pharmacokinetic changes in pregnancy (increased clearance) not significant for PASER; standard adult dose of 4 g twice daily is recommended.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
PASER (aminosalicylic acid) is a second-line antitubercular agent that inhibits folic acid synthesis. Administer with food to reduce GI upset; avoid concurrent use with salicylates due to additive GI irritation. Monitor for hepatotoxicity and hypersensitivity reactions. Drug levels should be monitored in patients with renal impairment.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
Take this medication with food to minimize stomach upset.,Do not crush or chew the tablets; swallow them whole.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems (yellowing of skin/eyes, dark urine) or allergic reactions (rash, fever) immediately.,Avoid alcohol during treatment.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MYAMBUTOL vs PASER, answered by our medical review team.
MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. PASER is a Antitubercular Agent that works by Inhibits cell wall synthesis in Mycobacterium tuberculosis by blocking mycolic acid synthesis. Also acts as a competitive inhibitor of folate synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MYAMBUTOL and PASER depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. The standard adult dose of PASER is: 4 g (8 capsules of 500 mg) orally every 8 hours, taken with food or an acidic beverage (e.g., orange juice) to enhance absorption.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MYAMBUTOL and PASER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . PASER is classified as Category C. PASER (aminosalicylic acid) is classified FDA pregnancy category C. First trimester: Limited human data; animal studies show no teratogenicity but some fetal toxicity at high doses. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.